^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Exelbine (vinorelbine) (Mitosis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Excerpt:
A proposed treatment algorithm for the management of hormone receptor (HR)-positive, HER2-negative MBC...Recommendations...Beyond second line...Available drugs for single-agent ChT include anthracyclines, taxanes, capecitabine, eribulin, vinorelbine, platinums and other agents.
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Title:
Combined Chemo-endocrine Therapy Maybe a New Option for HR+/HER2− Advanced Breast Cancer: A Prospective, Single-center Clinical Study of Fulvestrant plus Oral Vinorelbine
Published date:
11/22/2022
Excerpt:
This is the first exploratory study of Fulvestrant with oral Vinorelbine regimen in the treatment of HR+/HER2− recurrent and metastatic breast cancer conducted worldwide. The combinative chemoendocrine therapy was efficacious, safe and promising for patients with HR+/HER2− advanced breast cancer.
Secondary therapy:
fulvestrant
Source:
Title:
203P - Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer
Published date:
09/13/2021
Excerpt:
Open-label, multicentre, randomized phase II study evaluating Disease Control Rate (DCR) as primary endpoint in patients previously untreated with CT for HR+/HER2- ABC, pretreated with endocrine-therapy (ET) and no longer candidates to further ET. Arm A: Metronomic VNR 50 mg tw, Arm B: VNR 60 mg/m2 weekly at cycle 1...Primary endpoint was reached in both arms with DCR of 63.4% [95% CI: 52.0; 73.8] in arm A and 72.8% [95% CI: 61.8; 82.1] in arm B, respectively. Median PFS was 4.0 [95% CI: 2.8; 5.4] and 5.6 [95% CI: 4.4; 7.8] months in arm A and arm B, respectively. Median overall survival was 22.3 months [95% CI: 19.0; 27.3] in Arm A and 26.7 months [95% CI: 22.2; 37.8] in arm B.
Trial ID:
